Renal impairment – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:17:21 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Renal impairment – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study Comparing Intravenous Contrast CT with Non-Contrast CT for Patients with Acute Abdominal Pain and Reduced Kidney Function Using Iohexol https://clinicaltrials.eu/trial/study-comparing-intravenous-contrast-ct-with-non-contrast-ct-for-patients-with-acute-abdominal-pain-and-reduced-kidney-function-using-iohexol/ Wed, 29 Apr 2026 15:06:03 +0000 https://clinicaltrials.eu/trial/study-comparing-intravenous-contrast-ct-with-non-contrast-ct-for-patients-with-acute-abdominal-pain-and-reduced-kidney-function-using-iohexol/ This clinical trial is focused on patients experiencing an acute abdomen, which refers to sudden and severe abdominal pain that may require urgent medical attention. The study is particularly interested in patients who also have impaired renal function, meaning their kidneys are not working as well as they should. The trial will compare two types of computed tomography (CT) scans: one using an intravenous (IV) contrast called Omnipaque, which contains the active substance iohexol, and the other without any contrast.

The purpose of the study is to determine if using the IV contrast CT is better at diagnosing the cause of acute abdomen in these patients compared to a CT scan without contrast. Participants will be randomly assigned to receive either the contrast-enhanced CT or the non-contrast CT. The study will monitor participants for up to 90 days to observe outcomes such as overall survival, the need for kidney support treatments, and any changes in kidney function.

Throughout the study, researchers will also look at other factors, such as the severity of any acute kidney injury (AKI)</b) that might occur, any organ dysfunction, and the number of days participants spend out of the hospital. The study aims to provide valuable information on the best imaging approach for patients with acute abdomen and impaired kidney function, potentially improving diagnosis and treatment strategies in the future.

]]> Study on How Kidney Function Affects the Drug GS-5245 in Patients With Normal and Impaired Kidney Function https://clinicaltrials.eu/trial/study-on-how-kidney-function-affects-the-drug-gs-5245-in-patients-with-normal-and-impaired-kidney-function/ Wed, 29 Apr 2026 15:05:42 +0000 https://clinicaltrials.eu/trial/study-on-how-kidney-function-affects-the-drug-gs-5245-in-patients-with-normal-and-impaired-kidney-function/ This clinical trial is focused on studying how the body processes a medication called Obeldesivir in people with different levels of kidney function. The study involves participants with normal kidney function as well as those with renal impairment, which means their kidneys are not working as well as they should. The medication being tested, Obeldesivir, is given in the form of film-coated tablets, and the study will look at how it behaves in the body after a single dose.

The purpose of the study is to understand how kidney function affects the way Obeldesivir is absorbed, distributed, and eliminated by the body. Participants will be divided into groups based on their kidney function, and each group will receive a single dose of the medication. The study will monitor how the medication moves through the body and how it is broken down and removed. This will help researchers learn more about the safety and effectiveness of Obeldesivir in people with different levels of kidney function.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. The study aims to provide valuable information that could help improve treatment options for people with kidney issues in the future. Participants will be required to follow specific guidelines and attend regular check-ups to ensure their safety and the accuracy of the study results.

]]> Study on the Effects of AZD3427 on Kidney Function in Heart Failure Patients with Kidney Issues https://clinicaltrials.eu/trial/study-on-the-effects-of-azd3427-on-kidney-function-in-heart-failure-patients-with-kidney-issues/ Wed, 29 Apr 2026 15:00:07 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-azd3427-on-kidney-function-in-heart-failure-patients-with-kidney-issues/ This clinical trial is focused on studying the effects of a new treatment called AZD3427 on patients with two specific health conditions: Heart Failure with Reduced Ejection Fraction (HFrEF) and Renal Impairment. Heart failure with reduced ejection fraction is a condition where the heart muscle does not pump blood as well as it should, and renal impairment refers to reduced kidney function. The purpose of the study is to evaluate how AZD3427 affects blood flow in the kidneys of these patients.

Participants in the study will receive either the treatment AZD3427 or a placebo, which is a substance with no active medication. The study will also use a special imaging technique called Positron Emission Tomography (PET) to observe changes in kidney blood flow. In addition to AZD3427, other substances used in the study include Dopamine Hydrochloride, 15O-WATER, and Sodium Chloride, which are used to help with the imaging process or as part of the treatment protocol.

The study will be conducted over a period of time, during which participants will undergo various assessments to monitor their health and the effects of the treatment. These assessments will include checking vital signs, laboratory tests, and heart monitoring through an ECG (electrocardiogram). The study aims to provide valuable information on the safety and effectiveness of AZD3427 in improving kidney function in patients with heart failure and kidney impairment.

]]> Study on the Effects of Vonafexor, Rosuvastatin Zinc, and Iohexol on Kidney Function in Patients with Impaired Renal Function and Suspected MASH https://clinicaltrials.eu/trial/study-on-the-effects-of-vonafexor-rosuvastatin-zinc-and-iohexol-on-kidney-function-in-patients-with-impaired-renal-function-and-suspected-mash/ Wed, 29 Apr 2026 14:47:48 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-vonafexor-rosuvastatin-zinc-and-iohexol-on-kidney-function-in-patients-with-impaired-renal-function-and-suspected-mash/ This clinical trial is focused on studying the effects of a medication called Vonafexor on individuals with impaired kidney function and a condition known as Metabolic Associated Steatohepatitis (MASH). MASH is a liver disease that often occurs in people who are overweight or have diabetes. The purpose of the study is to understand how Vonafexor affects kidney function in people who have mild to moderate kidney issues and are suspected of having MASH.

Participants in the study will receive Vonafexor in the form of tablets. The study will also involve the use of a diagnostic agent called Iohexol, which is a type of contrast used to help assess kidney function. Some participants may receive a placebo instead of the active medication. The study will take place over several weeks, with regular check-ups to monitor kidney function and overall health. Participants will have their kidney function measured at different times during the study to see how it changes with the treatment.

The study aims to provide valuable information on how Vonafexor can help manage kidney function in people with suspected MASH. By participating, individuals will contribute to research that could lead to better treatments for those with similar health conditions. The study will also monitor any side effects or changes in health to ensure the safety of all participants.

]]>